Patient leaflet - Twinrix Adult
1. What Twinrix Adult is and what it is used for
Twinrix Adult is a vaccine used in adults and adolescents 16 years of age and above to prevent two diseases: hepatitis A and hepatitis B. The vaccine works by causing the body to produce its own protection (antibodies) against these diseases.
- Hepatitis A: Hepatitis A is an infectious disease, which can affect the liver. This disease is caused by the hepatitis A virus. The hepatitis A virus can be passed from person to person in food and drink, or by swimming in water contaminated by sewage. Symptoms of hepatitis A begin 3 to 6 weeks after coming into contact with the virus. These consist of nausea (feeling sick), fever and aches and pains. After a few days the whites of eyes and skin may become yellowish (jaundice). The severity and type of symptoms can vary. Young children may not develop jaundice. Most people recover completely but the illness is usually severe enough to keep people ill for about a month.
- Hepatitis B: Hepatitis B is caused by the hepatitis B virus. It causes the liver to become swollen (inflamed). The virus is found in body fluids such as blood, semen, vaginal secretions, or saliva (spit) of infected people.
Vaccination is the best way to protect against these diseases. None of the components in the vaccine are infectious.
2. What you need to know before you receive Twinrix AdultTwinrix Adult should not be given if you are allergic to:
-
– the active substances or any of the other ingredients of this medicine (listed in section 6).
-
– neomycin.
Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.
- you have previously had an allergic reaction to any vaccine against hepatitis A and hepatitis B
diseases.
- you have a severe infection with a high temperature (over 38°C). A minor infection such as a
cold should not be a problem, but talk to your doctor first.
Warnings and precautions
Talk to your doctor or pharmacist before receiving Twinrix Adult if
- you have experienced any health problems after previous administration of a vaccine.
- you have a poor immune system due to illness or drug treatment.
- you have a bleeding problem or bruise easily.
Fainting can occur (mostly in adolescents) following, or even before, any needle injection. Therefore tell the doctor or nurse if you fainted with a previous injection.
A poor response to the vaccine, possibly without achieving protection against hepatitis A, has been observed in obese people. A poor response to the vaccine, possibly without achieving protection against hepatitis B, has also been observed in older people, men rather than women, smokers, obese people, and people with long standing illnesses, or people on some type of drug treatments. Your doctor may advise you to have a blood test after you have completed the course of vaccinations to check if you have made a satisfactory response. If not, your doctor will advise you on the possible need to have extra doses.
Other medicines and Twinrix Adult
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think that you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this vaccine. It is not known if Twinrix Adult passes into breast milk, however the vaccine is not expected to cause problems in breast-fed babies.
Twinrix Adult contains neomycin and sodium
Please tell your doctor if you have had an allergic reaction to neomycin (antibiotic).
This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.
-
3. How Twinrix Adult is given
You will receive a total of three injections over 6 months. Each injection is given on a separate visit. The first dose will be given on an elected date. The remaining two doses will be given one month, and six months after the first dose.
- First dose:
- Second dose:
at an elected date
1 month later
- Third dose:
6 months after the first dose
Twinrix Adult can also be given as a total of three doses over 1 month. This schedule may be given to adults only needing a rapid protection (e.g. overseas travellers). The first dose will be given on an elected date. The remaining 2 doses will be given 7 days and 21 days after the first dose. A fourth dose is recommended at 12 months.
First dose: | at an elected date |
Second dose: | 7 days later |
Third dose: | 21 days after the first dose |
Fourth dose: | 12 months after the first dose |
Your doctor will advise on the possible need for extra doses, and future booster dosing.
As indicated in section 2, a poor response to the vaccine, possibly without achieving protection against hepatitis B, is more common in older people, men rather than women, smokers, obese people, and people with long standing illnesses, or people on some type of drug treatments. Your doctor may advise you to have a blood test after you have completed the course of vaccinations to check if you have made a satisfactory response. If not, your doctor will advise you on the possible need to have extra doses.
If you miss a scheduled injection, talk to your doctor and arrange another visit.
Make sure you finish the complete vaccination course of three injections. If not, you may not be fully protected against the diseases.
The doctor will give Twinrix Adult as an injection into your upper arm muscle.
The vaccine should not be given (deep) into the skin or intramuscularly into the buttock because protection may be less.
The vaccine should never be given into a vein.
If you have any further questions on the use of this vaccine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this vaccine can cause side effects, although not everybody gets them.
Side effects that may occur are the following:
Very common (These may occur in 1 in 10 doses or more of the vaccine):
- Headache
- Pain and redness at the injection site
- Tiredness
Common (These may occur in up to 1 in 10 doses of the vaccine):
- Diarrhoea, nausea
- Swelling, bruising or itching at the injection site
- Generally feeling unwell
Uncommon (These may occur in up to 1 in 100 doses of the vaccine):
- Dizziness
- Vomiting, stomach pain
- Aching muscles
- Upper respiratory tract infection
- Fever equal to or greater than 37.5°C
Rare (These may occur in up to 1 in 1,000 doses of the vaccine):
- Swollen glands in the neck armpit or groin (lymphadenopathy)
- Loss of skin sensitivity to pain or touch (hypoaesthesia)
- Feeling of pins and needles (paraesthesia)
- Rash, itching
- Joint pain
- Loss of appetite
- Low blood pressure
- Flu-like symptoms such as high temperature, sore throat, runny nose, cough and chills
Very rare (These may occur in up to 1 in 10,000 doses of the vaccine):
Side effects occurred very rarely during clinical studies or routine use of the vaccine or with individual hepatitis A and hepatitis B vaccines include:
- Reduction in blood platelets, which increases risk of bleeding or bruising (thrombocytopenia)
- Purple or red brown spots visible through the skin (thrombocytopenic purpura)
- Swelling or infection of the brain (encephalitis)
- Degenerative disease of the brain (encephalopathy)
- Inflammation of nerves (neuritis)
- Numbness or weakness of the arms and legs (neuropathy), paralysis
- Fits or seizures
- Swelling of the face, mouth or throat (angioneurotic oedema)
- Purple or reddish-purple bumps on the skin (lichen planus), serious skin rashes (erythema multiforme), hives
- Joint swelling, muscular weakness
- Infection around the brain which may give severe headache with stiff neck and sensitivity to light (meningitis)
- Inflammation of some blood vessels (vasculitis)
- Serious allergic reactions (anaphylaxis, anaphylactoid reactions and mimicking serum sickness). Signs of serious allergic reactions may be rashes that may be itchy or blistering, swelling of the eyes and face, difficulty in breathing or swallowing, a sudden drop in blood pressure and loss of consciousness. Such reactions may occur before leaving the doctor’s surgery. However, if you get any of these symptoms you should contact a doctor urgently.
- Abnormal laboratory liver test results
- Multiple sclerosis, swelling of the spinal cord (myelitis)
- Drooping eyelid and sagging muscles on one side of the face (facial palsy)
- A temporary inflammation of the nerves, causing pain, weakness and paralysis in the extremities and often progressing to the chest and face (Guillain-Barre syndrome)
- A disease of the nerves of the eye (optic neuritis)
- Immediate injection site pain, stinging and burning feeling
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Twinrix Adult
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.
Store in a refrigerator (2°C – 8°C).
Store in the original package in order to protect from light.
Do not freeze. Freezing destroys the vaccine.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Twinrix Adult contains
The active substances are:
720 ELISA Units
20 micrograms
Hepatitis A virus (inactivated)1,2
Hepatitis B surface antigen3,4
-
1Produced on human diploid (MRC-5) cells
-
2Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al3+
-
3Produced in yeast cells (Saccharomyces cerevisiae ) by recombinant DNA technology
-
4Adsorbed on aluminium phosphate 0.4 milligrams Al3+
– The other ingredients in Twinrix Adult are: sodium chloride, water for injections.
What Twinrix Adult looks like and contents of the pack
Suspension for injection in pre-filled syringe.
Twinrix Adult is a white, slightly milky liquid presented in a glass pre-filled syringe (1 ml).
Twinrix Adult is available in packs of 1, 10, and 25 with or without needles.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
GlaxoSmithKline Biologicals s.a.
Rue de l’Institut 89
B-1330 Rixensart
Belgium
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgique/Belgie/Belgien
GlaxoSmithKline Pharmaceuticals SA/NV
Tél/Tel: + 32 10 85 52 00
Etnrapua
GlaxoSmithKline Biologicals SA
Ten.: +359 80018205
Česká republika
GlaxoSmithKline s.r.o.
Tel: + 420 2 22 00 11 11
Danmark
GlaxoSmithKline Pharma A/S
Tlf: + 45 36 35 91 00
Deutschland
GlaxoSmithKline GmbH & Co. KG
Tel: + 49 (0)89 360448701
Eesti
Lietuva
GlaxoSmithKline Biologicals SA
Tel. +370 80000334
Luxembourg/Luxemburg
GlaxoSmithKline Pharmaceuticals SA/NV
Tel/Tel: + 32 10 85 52 00
Magyarorszag
GlaxoSmithKline Biologicals SA
Tel.: +36 80088309
Malta
GlaxoSmithKline Biologicals SA
Tel: +356 80065004
Nederland
GlaxoSmithKline BV Tel: + 31 (0)33 2081100
Norge
GlaxoSmithKline Biologicals SA
Tel: +372 8002640
EXÀàôa
GlaxoSmithKline Movonpôoœnn A.E.B.E.
Tql: + 30 210 68 82 100
España
GlaxoSmithKline, S.A.
Tel: + 34 900 202 700
France
Laboratoire GlaxoSmithKline
Tél: + 33 (0) 1 39 17 84 44
Hrvatska
GlaxoSmithKline Biologicals SA
Tel.: +385 800787089
Ireland
GlaxoSmithKline (Ireland) Ltd
Tel: + 353 (0)1 495 5000
Ísland
Vistor hf.
Sími: +354 535 7000
Italia
GlaxoSmithKline S.p.A.
Tel: + 39 (0)45 7741111
Kùnpoç
GlaxoSmithKline Biologicals SA
Tql: +357 80070017
Latvija
GlaxoSmithKline Biologicals SA
Tel: +371 80205045
GlaxoSmithKline AS
Tlf: + 47 22 70 20 00
Österreich
GlaxoSmithKline Pharma GmbH
Tel: + 43 (0)1 970750
Polska
GSK Services Sp. z o.o.
Tel.: + 48 (22) 576 9000
Portugal
Smith Kline & French Portuguesa – Produtos
Farmacéuticos, Lda.
Tel: + 351 21 412 95 00
Romania
GlaxoSmithKline Biologicals SA
Tel: +40 800672524
Slovenija
GlaxoSmithKline Biologicals SA
Tel: +386 80688869
Slovenská republika
GlaxoSmithKline Biologicals SA
Tel.: +421 800500589
Suomi/Finland
GlaxoSmithKline Oy
Puh/Tel: + 358 (0)10 30 30 30
Sverige
GlaxoSmithKline AB
Tel: + 46 (0)8 638 93 00
United Kingdom (Northern Ireland)
GlaxoSmithKline Biologicals SA
Tel: +44(0)800 221441
This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:.
The following information is intended for healthcare professionals only: Upon storage, a fine white deposit with a clear colourless layer above may be observed.
The vaccine should be re-suspended before use. When re-suspended, the vaccine will have a uniform hazy white appearance.
Re-suspension of the vaccine to obtain a uniform hazy white suspension
The vaccine should be re-suspended following the steps below.
-
1. Hold the syringe upright in a closed hand.
-
2. Shake the syringe by tipping it upside down and back again.
-
3. Repeat this action vigorously for at least 15 seconds.
-
4. Inspect the vaccine again: